title: Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.
abstract: To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to ziprasidone, three 52-week, open-label extension studies of ziprasidone in outpatients (N=185) with schizophrenia or schizoaffective disorder successfully completing one of three, 6-week switch studies were carried out. Pre-switch treatment consisted of risperidone (n=43), olanzapine (n=71), or conventional antipsychotic agents (n=71). The maximum length of exposure to ziprasidone was 58 weeks. Nonfasting total cholesterol and triglyceride levels were obtained at baseline and at weeks 6, 19, 32, 45, and 58. Weight was measured at baseline and during each follow-up visit; height was recorded at baseline for the purpose of body mass index (BMI) calculation. Efficacy measures included the Positive and Negative Syndrome Scale and Clinical Global Impression-Severity scale which were obtained at baseline and major follow-up points. Clinically significant sustained improvements in weight, BMI, total cholesterol, and triglyceride levels were observed among patients switched to ziprasidone from risperidone or olanzapine. Switching from conventional antipsychotics was not associated with significant changes in weight and lipid parameters. Mean reductions in weight from baseline to study endpoint were 9.8 kg (p<0.001) and 6.9 kg (p<0.005) for patients previously treated with olanzapine and risperidone, respectively. These findings demonstrate that switching from risperidone or olanzapine to ziprasidone is associated with sustained, clinically significant improvements in weight and plasma lipids.
authors.affiliation: Department of Psychiatry, Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, IL, USA. pweiden@psych.uic.edu
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Weiden
authors.forename: John W
authors.initials: JW
authors.lastname: Newcomer
authors.forename: Antony D
authors.initials: AD
authors.lastname: Loebel
authors.forename: Ruoyong
authors.initials: R
authors.lastname: Yang
authors.forename: Harold E
authors.initials: HE
authors.lastname: Lebovitz
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects* / Q000502:physiology; D010054:Brief Psychiatric Rating Scale; D003430:Cross-Sectional Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D001523:Mental Disorders / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D000077152:Olanzapine; D010879:Piperazines / Q000627:therapeutic use*; D012189:Retrospective Studies; D016037:Single-Blind Method; D013844:Thiazoles / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D008055:Lipids; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; C092292:ziprasidone; D000077152:Olanzapine